Research programme: histamine H3 receptor antagonists - PfizerAlternative Names: 475071; WAY 361563; WAY-361046; WAY-364416
Latest Information Update: 29 Sep 2011
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Amines; Small molecules
- Mechanism of Action Histamine H3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cognition disorders; Schizophrenia